Research & Educational Use Only. Not medical advice. Not for human consumption.
📈 GH Secretagogue

Ipamorelin (10 mg Vial) Dosage Protocol

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and selective growth hormone secretagogue. Identified as the first highly selective GHRP, it stimulates GH release through ghrelin receptors without significantly elevating cortisol, ACTH, or prolactin — a key advantage over earlier GHRPs.

âš¡ Quickstart Highlights

Reconstitution
3.0 mL BAC water → 3.33 mg/mL
Per-Dose Range
100–300 mcg per injection
1 U-100 Unit =
33.3 mcg
Half-life
~1.5–2.5 hours

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: 1–3× daily, typically on empty stomach

WeekDose Per InjectionFrequencyU-100 Units
Weeks 1–2100 mcgOnce daily3 units
Weeks 3–4150–200 mcgOnce or twice daily4.5–6 units
Weeks 5–12200–300 mcgOnce or twice daily6–9 units
Best administered on an empty stomach (30 min before eating or 2 hrs after a meal) to maximize GH pulse amplitude. Pre-sleep dosing leverages the natural nocturnal GH surge.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water.
  2. Inject slowly down the inside glass wall; avoid foaming.
  3. Gently swirl until dissolved. Do not shake.
  4. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item8 Weeks (once daily)12 Weeks (twice daily)
Ipamorelin vials (10 mg each)2 vials6 vials
Insulin syringes (30–50 unit)56168
Bacteriostatic water (10 mL)1 × 10 mL2–3 × 10 mL
Alcohol swabs2 × 100-pack3 × 100-pack

Mechanism of Action

Ipamorelin is a fifth-generation growth hormone releasing peptide (GHRP) that acts as an agonist at the ghrelin receptor (GHS-R1a) in the pituitary gland. It produces a rapid, selective GH pulse peaking approximately 40 minutes post-injection with a duration of approximately 3 hours.

Unlike earlier GHRPs (GHRP-2, GHRP-6, hexarelin), ipamorelin does not significantly stimulate cortisol, ACTH, or prolactin at standard research doses. This selectivity profile is its primary distinguishing characteristic and makes extended-cycle protocols more feasible. When combined with CJC-1295 (No DAC) or other GHRH analogs, synergistic GH pulse amplification is observed, as the two compounds act on complementary receptor pathways.

Research Findings & Safety Profile

Storage

StateTemperatureDurationNotes
Lyophilized−20°C (−4°F)Up to 24 monthsDry, dark conditions
Reconstituted2–8°C (35–46°F)Up to 28 daysAvoid freeze-thaw
âš  Research Use Only: Ipamorelin is an investigational compound. All research protocols extrapolated from preclinical and limited human pharmacokinetic data. Best administered on an empty stomach to maximize GH pulse amplitude.

References

1
Raun K et al. 'Ipamorelin, the first selective growth hormone secretagogue' — Eur J Endocrinol, 1998 View source ↗
2
Svensson J et al. 'Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure' — J Clin Endocrinol Metab, 1998 View source ↗
3
Walker RF. 'Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?' — Clinical Interventions in Aging (PMC) View source ↗